Pepsinogen I / Pepsinogen II (PGI/PGII)

Short Description:

Send email to us

Product Detail

Product Tags

Key Product Characteristics

Kit Name: Pepsinogen I / Pepsinogen II Detection Kit

Method: Fluorescence dry quantitative immunoassay

Assay measuring range:

PGⅠ：3.0ng/mL~200.0ng/mL；

PGⅡ：1.5ng/mL~100.0ng/mL

Incubation time: 10 minutes

Sample: Human serum, plasma (EDTA-K2 anticoagulant) and whole blood (EDTA-K2 anticoagulant)

Reference range:

PGⅠ＞70.0ng/mL，PGⅡ＜27.0ng/mL

Storage and Stability:

✭Detection Buffer is stable for 12 months at 2°~8°C.

✭Sealed Test Device is stable for 12 months at 2°C～30°C.

Introduction

•Pepsinogen (PG) is the inactive precursor of pepsin and consists of 375 amino acids. Based on its biochemical properties, immunogenicity, cellular origin and intra-tissue distribution, PG can be divided into two subgroups, PG I and PG II.

•PGⅠ is mainly secreted by the main cells and mucus neck cells of the fundic glands; PGⅡ is also produced by the main cells and mucus neck cells of the fundic glands, the mucus neck cells of the pyloric glands of the cardia and the gastric sinus, and the Brunner's gland in the upper duodenum, and a small amount of PGⅡ is also produced by the prostate and the pancreas.

•Serum PGⅠ and PGⅡ reflect the number of gastric mucosal glands and cells, and also indirectly reflect the secretory function of different parts of the gastric mucosa. When pathological changes occur in the gastric mucosa, the serum PG level also changes. Since the stomach is almost the only source of PG, monitoring the concentration of PG in serum can be used as a means to monitor the status of the gastric mucosa.

Consensus & Guidelines

•《Asia-Pacific consensus guidelines on gastric cancer prevention（2008）》

Low serum pepsinogen I levels and low PG I/II ratio may be useful as a marker to identify populations at high risk for gastric cancer.(Ⅱa，B)

•《Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening》

For screening gastric cancer in high-incidence regions other than in Japan, and for high-risk patient management, further studies using PG test to be worthwhile.

•《Kyoto global consensus report on Helicobacter pylori gastritis（2015）》

Serological tests (pepsinogen I and II and H. pylori antibody) are useful for identifying individuals at increased risk for gastric cancer.

•《Chinese consensus on chronic gastritis (2017, Shanghai)》

Serum pepsinogen (PG) I, PG II and gastrin-17 may help assess the presence and extent of gastric mucosal atrophy. Serum PG I, PG II, and PG I/II ratio combined with anti-H. pylori antibody test contribute to risk stratification management.

•《Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019》

Serum pepsinogen levels can predict extensive atrophic gastritis.

Low pepsinogen I serum levels or/and low pepsinogen I/II ratio identify patients with advanced stages of atrophic gastritis and endoscopy is recommended for these patients, particularly if H. pylori serology is negative (moderate quality evidence, strong recommendation).

Clinical Applications

• Early Screening for Gastric Cancer

•Determination index and efficacy evaluation index of peptic ulcer and recurrence after cure

•Dynamic monitoring indicators of gastric mucosal function